GERN

Geron Corporation

Healthcare
Biotechnology
$866M market cap

Forecast run · Sep 14, 2026Upside rank 868 of 3,136

Model Signal

ForecastQ Daily Probabilities

47.6%

44.4%

24.4%

Analyst Consensus

Recommendation2.32/5 Buy

Last price$1.35

Price target$5.89

Implied move+336.3%

Analysts22

ForecastQ Portfolios

GERN is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.